Likewise, BRCA1 methylation in ovarian cancer (~16%) mirrors BRCA1 genetic loss and correlates (in certain assay types) with treatment response, supporting methylation as both a functional alteration and a biomarker across cancers [92]. This evidence concerns the gene BRCA1 and ovarian carcinoma.